SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Sponsor

Amsterdam UMC, location VUmc (Other)

Overall Status

Completed

CT.gov ID

NCT01744236

Collaborator

EU FP7: SAFEGUARD consortium (Other)

Enrollment

Location

Arms

Duration (Months)

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.

Condition or Disease	Intervention/Treatment	Phase
Type 2 Diabetes	Drug: Liraglutide Drug: Sitagliptin Drug: Exenatide Drug: Liraglutide placebo Drug: Sitagliptin placebo Drug: Exenatide placebo Drug: L-NMMA	Phase 4

Detailed Description

GLP-1 receptors are present in most organ systems of the human body, and pharmacological interventions enhancing GLP-1 activity may influence the function of these organs. The use of GLP-1 receptor agonists (GLP-1RA) and DPP-4 inhibitors (DPP-4i) has been associated with an increased heart rate, acute pancreatitis and acute renal failure. To date, studies in humans detailing the effects of these drugs on these organ systems, biological processes and underlying mechanisms, which could explain these associations, are lacking.

Therefore, as part of the EU-FP7 SAFEGUARD program, the present study will aim to detail the (mechanisms underlying the) actions of GLP-1RA and DPP-4i on the cardiovascular, renal and gastrointestinal system in healthy obese subjects and patients with T2DM.

In the main study, sixty patients with type 2 diabetes will undergo two interventions within the same protocol in order to assess changes in the outcome parameters:

acute study = acute infusion with exenatide or placebo (to assess the cardiovascular and renal effects)
long-term study = 12 weeks of treatment with liraglutide, sitagliptin or placebo (to assess the cardiovascular, renal and gastrointestinal effects)

In a substudy (termed 'acute MRI study'), twelve patients with type 2 diabetes will undergo an additional acute intervention study with exenatide (to assess the pancreatic effects)

In a substudy (termed 'pilot-study'), ten healthy obese subjects will undergo a similar acute study like the patients with type 2 diabetes (to assess the cardiovascular and renal effects). Moreover, in these healthy subjects, the effects of exenatide during L-NMMA infusion will be assessed.

Study Design

Study Type:

Interventional

Actual Enrollment :

70 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naïve Patients With Type 2 Diabetes (T2DM).

Study Start Date :

Apr 1, 2013

Actual Primary Completion Date :

Aug 1, 2015

Actual Study Completion Date :

Aug 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Liraglutide (main study, long-term intervention) This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks	Drug: Liraglutide Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily. Drug: Sitagliptin placebo Sitagliptin-placebo be given once daily for 12 weeks.
Experimental: Sitagliptin (main study, long-term intervention) This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks	Drug: Sitagliptin Sitagliptin 100mg will be given once daily for 12 weeks. Drug: Liraglutide placebo Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Placebo Comparator: Placebo (main study, long-term intervention) This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks	Drug: Liraglutide placebo Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily. Drug: Sitagliptin placebo Sitagliptin-placebo be given once daily for 12 weeks.
Experimental: Exenatide (main study, acute intervention) Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).	Drug: Exenatide Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
Placebo Comparator: Placebo (main study, acute intervention) Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).	Drug: Exenatide placebo Exenatide-placebo (saline) will be administered intravenously
Other: Acute MRI intervention study In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.	Drug: Exenatide Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests Drug: Exenatide placebo Exenatide-placebo (saline) will be administered intravenously
Other: Pilot-study In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.	Drug: Exenatide Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests Drug: Exenatide placebo Exenatide-placebo (saline) will be administered intravenously Drug: L-NMMA

Outcome Measures

Primary Outcome Measures

Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements. [12 weeks]
Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on Glomerular Filtration Rate, measured by the inulin-clearance technique. [12 weeks]
Changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on pancreatic exocrine function, measured as fecal Elastase-1. [12 weeks]

Secondary Outcome Measures

Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following cardiovascular parameters: [12 weeks]
Blood pressure and heart rate Hemodynamic variables (blood pressure, heart rate, stroke volume, cardiac output/-index/-contractility, systemic vascular resistance) derived from non-invasive beat-to-beat finger blood pressure measurements Cardiac autonomic nervous system function Microvascular function and vasomotion Arterial stiffness Lipid spectrum Glycemic variables (HbA1c, fasting and postprandial glucose) Body anthropometrics: body weight, height, BMI and waist circumference Body fat content
Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following renal parameters: [12 weeks]
Effective renal plasma flow (ERPF) Renal tubular function Renal damage, measured by urine biomarkers
Changes from baseline following infusion of GLP-1RA (acute effects*) and changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on the following gastrointestinal parameters: [12 weeks]
Pancreatic exocrine function (* In the acute intervention only exocrine pancreatic function is assessed) Pancreatic structure Pancreatic enzymes Gallbladder emptying speed Liver enzymes Hepatic structure/steatosis Gastric emptying

Eligibility Criteria

Criteria

Ages Eligible for Study:

35 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age between 35 and 75 years.
Females must be post-menopausal (no menses >1 year).
Type 2 diabetes (HbA1c 6.5-9% DCCT or 48-75 mmol/mol IFCC), who are being treated with a stable dose of oral antihyperglycemic agents (either metformin alone, SU alone or a combination of metformin and SU) for at least 3 months prior to inclusion.
BMI 25 - 40 kg/m2
Caucasian
Signed informed consent

Exclusion Criteria:

GFR < 60 mL/min/1.73m2
Current / chronic use of the following medication: thiazolidinediones, GLP-1RA, DPP-4i, glucocorticoids, NSAIDs, insulin, antimicrobial agents, chemotherapeutics or immune suppressants. Subjects on diuretics will only be excluded when these drugs (e.g. hydrochlorothiazide) cannot be stopped for the duration of the study.
History of or actual pancreatic disease or impaired pancreatic exocrine function
Active liver disease
History of or actual malignancy (with the exception of basal cell carcinoma)
Current urinary tract infection and active nephritis
Recent (<6 months) history of cardiovascular disease, including acute coronary syndrome, stroke, transient ischemic neurologic disorder or chronic heart failure (New York Heart Association grade II-IV)
Current atrial fibrillation
Chronic infectious or auto-immune disease
Substance and/or alcohol abuse
History of allergy/hypersensitivity to any of the test agents
Complaints compatible with or established gastroparesis and/or neurogenic bladder
Any condition that has been recognized as a contra-indication for the use of GLP-1RA and DPP-4i, as listed in the respective SPCs
History of or actual (severe) mental illness
Inability to understand the study protocol and/or inability to give informed consent
History of claustrophobia or presence of metal objects/implants (because of MRI protocol)

For the preceding Pilot study, we will include:

Males
Age between 18 and 50 years
BMI 25 - 40 kg/m2
Caucasian

The exclusion criteria for the preceding pilot study are similar to the exclusion criteria of the main study, with the additions of:

Subjects with a fasting plasma glucose ≥5.6 mmol/L, a 2-hour glucose of ≥7.8 mmol/L after a 75-grams oral glucose tolerance test, or a HbA1c of ≥6.5%
Subjects using any kind of medication